Article
A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
Scientific reports - 23 Oct 2017
Kopinja Johnny, Sevilla Raquel S, Levitan Diane, Dai David, Vanko Amy, Spooner Edward, Ware Chris, Forget Robert, Hu Kun, Kral Astrid, Spacciapoli Peter, Kennan Richard, Jayaraman Lata, Pucci Vincenzo, Perera Samanthi, Zhang Weisheng, Fischer Christian, Lam Michael H
Abstract excerpt
Mutations in IDH1 are highly prevalent in human glioma. First line treatment is radiotherapy, which many patients often forego to avoid treatment-associated morbidities. The high prevalence of IDH1 mutations in glioma highlights the need for brain-penetrant IDH1 mutant-selective inhibitors as an alternative therapeutic option. Here, we have explored the utility of such an inhibitor in IDH1 mutant patient-derived...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.